Bob Gabriel is the Senior Vice President and General Manager of Bioclinica's Financial Lifecycle Solutions (FLS) division. The FLS suite of financial lifecycle products assists with managing the global automation and financial management of clinical trials and includes ClinPay, a proprietary transaction engine and secure online clinical trial payment network; ClinPlan, a budget management and cash forecasting solution; and ClinDebit, a patient reimbursement solution. These solutions are capable of handling budget and forecast development, contract creation and management, contract translation, automated payment generation and accounting and reporting.
Most recently, Bob was Senior Vice President, Professional Services with Information Builders, providers of business intelligence and process integration solutions to the pharmaceutical R&D, healthcare, banking and financial and insurance sectors, where he had global responsibility for consulting, operations and delivery functions. His 30-year career also includes senior leadership positions at Siebel, PDS, and Cap Gemini, giving him in-depth knowledge of complex ecosystems comprising enterprise resource planning (ERP), financial, customer relationship management (CRM), human resources management system (HRMS) and other critical applications.
While Bob is relatively new to both Bioclinica and clinical trials, his background in delivering professional and consultative services for driving revenue, customer satisfaction, profitability and growth complements the FLS aim of reducing workload, time and costs through automation and unprecedented transparency and workflow.
Bob firmly believes that Bioclinica can become the market leader for FLS. Clinverse, before the acquisition by Bioclinica, defined this market starting with their automated payment services. The primary competition continues to be manual financial processes, and although additional companies have entered this space, they tend to offer only a small subset of the full Bioclinica suite. As such, Bob views his new position as a ground-level opportunity to evolve the value proposition of FLS and further establish the market, by facilitating quicker and more accurate payments leading to increased site and subject satisfaction—his goal is to establish Bioclinica as the number one payment system in the market.